Is Sharda Cropchem a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Sharda Cropchem Ltd is a average quality company .

Is Sharda Cropchem undervalued or overvalued?

The key valuation ratios of Sharda Cropchem Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone .

What is Sharda Cropchem share price return in the past 10 years?

Sharda Cropchem Ltd share price has appreciated 12% annually (CAGR) over the past ten years.

Is Sharda Cropchem a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Sharda Cropchem Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

Sharda Cropchem Ltd - Stock Valuation and Financial Performance

Name: Sharda Cropchem
Brand: Sharda Cropchem

BSE: 538666 | NSE: SHARDACROP | Pesticides & Agrochemicals | Small Cap

Place order

Sharda Cropchem Share Price

₹792.70 -40.70 -4.88%
as on 20-Dec'24 16:59

10 Year X-Ray of Sharda Cropchem:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Standalone Basis ^P Consolidated Basis ^P

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
ROCE % ⓘ	27.4%	38.6%	34.1%	28.7%	19.6%	18%	20.8%	24.3%	22.8%	9.5%	-
Value Creation Index ⓘ	1.0	1.8	1.4	1.1	0.4	0.3	0.5	0.7	0.6	-0.3	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	769	934	1,129	1,470	1,604	1,616	2,033	2,946	3,313	2,603	2,932
Sales YoY Gr.	-	21.5%	20.8%	30.2%	9.1%	0.8%	25.8%	45%	12.4%	-21.4%	-
Adj EPS ⓘ	11	18.3	20.9	21.8	16	26	22	34.9	42	18.1	26.7
YoY Gr.	-	65.9%	14.6%	4.1%	-26.6%	62.6%	-15.3%	58.4%	20.5%	-57%	-
BVPS (₹) ⓘ	65.1	81.7	98.6	118.1	130	145.3	166.6	191.9	221.9	234.1	233.5
Adj Net Profit ⓘ	99.3	165	189	196	144	234	199	315	379	163	241
Cash Flow from Ops. ⓘ	14.2	142	123	-14.6	513	53	202	277	140	163	-
Debt/CF from Ops. ⓘ	2.7	0	0	-11.6	0	0	0.3	0.1	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	14.5%	10.2%	8.6%	-21.4%
Adj EPS ⓘ	5.7%	2.5%	-6.4%	-57%
BVPSⓘ	15.3%	12.5%	12%	5.5%
Share Price	12%	29.6%	36.5%	83.8%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	TTM
Return on Equity % ⓘ	18	24.9	23.2	20.1	12.9	18.9	14.1	19.5	20.3	7.9	11.4
Op. Profit Mgn % ⓘ	21.9	25.4	24.7	24.1	20.1	18.2	18.3	22	17.6	8.8	12.7
Net Profit Mgn % ⓘ	12.9	17.6	16.7	13.4	9	14.5	9.8	10.7	11.4	6.3	8.2
Debt to Equity ⓘ	0.1	0	0	0.2	0	0	0.1	0	0	0	0
Working Cap Days ⓘ	249	304	336	358	361	363	347	306	351	469	145
Cash Conv. Cycle ⓘ	76	74	72	125	92	93	100	98	126	183	72

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to 11.40%

Sales growth has been subdued in last 3 years 8.59%

Net Profit has been subdued in last 3 years -6.40%

Sales growth is not so good in last 4 quarters at 5.50%

Latest Financials - Sharda Cropchem Ltd.

	Standalone	Consolidated
TTM EPS (₹)	26.7	24.1
TTM Sales (₹ Cr.)	2,932	3,507
BVPS (₹.) ⓘ	233.5	254.2
Reserves (₹ Cr.) ⓘ	2,043	2,204
P/BV ⓘ	3.40	3.12
PE ⓘ	29.65	32.84

From the Market
52 Week Low / High (₹)	318.00 / 886.35
All Time Low / High (₹)	99.00 / 886.35
Market Cap (₹ Cr.)	7,152
Equity (₹ Cr.)	90.2
Face Value (₹)	10
Industry PE ⓘ	42.5

Management X-Ray of Sharda Cropchem:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Sharda Cropchem

Price Calculator

Price Chart

Price to Earnings

Enterprise Value to EBIT

Price to Book-Value

Price to Sales

Dividend History

Analyst's Notes

This is a premium feature, Please click here to check our solutions.

Key Ratios of Sharda Cropchem

Standalone Basis Consolidated Basis

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Sales	769	934	1,129	1,470	1,604	1,616	2,033	2,946	3,313	2,603
Operating Expenses ⓘ	617	700	851	1,129	1,326	1,376	1,660	2,344	2,809	2,411
Manufacturing Costs	0	0	0	0	0	1	0	0	0	0
Material Costs	481	573	700	956	1,088	1,113	1,369	2,012	2,337	1,953
Employee Cost	17	20	23	26	26	28	31	35	37	34
Other Costs ⓘ	118	106	128	147	212	234	260	296	434	424
Operating Profit ⓘ	152	235	279	341	278	240	373	602	504	192
Operating Profit Margin (%)	19.8%	25.1%	24.7%	23.2%	17.3%	14.9%	18.3%	20.4%	15.2%	7.4%
Other Income ⓘ	28	63	56	33	56	120	97	48	174	271
Interest ⓘ	7	7	8	14	19	15	14	13	18	21
Depreciation ⓘ	23	35	56	70	99	137	170	245	248	267
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Profit Before Tax ⓘ	150	256	270	290	217	209	285	392	411	175
Tax ⓘ	52	84	81	97	73	17	75	110	87	38
Profit After Tax	98	172	189	193	144	192	210	283	325	137
PAT Margin (%)	12.7%	18.4%	16.7%	13.2%	9.0%	11.9%	10.3%	9.6%	9.8%	5.3%
Adjusted EPS (₹)	10.8	19.1	20.9	21.4	16.0	21.3	23.3	31.4	36.0	15.2
Dividend Payout Ratio (%)	23%	16%	19%	19%	25%	19%	22%	19%	17%	20%

Balance Sheet

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Equity and Liabilities
Shareholders Fund	587	737	890	1,065	1,173	1,311	1,503	1,732	2,002	2,112
Share Capital ⓘ	90	90	90	90	90	90	90	90	90	90
Reserves ⓘ	497	647	800	975	1,083	1,221	1,412	1,641	1,912	2,022
Minority Interest	0	0	0	0	0	0	0	0	0	0
Debt	38	2	0	170	0	0	68	38	0	0
Long Term Debt	0	0	0	0	0	0	0	0	0	0
Short Term Debt	38	2	0	170	0	0	68	38	0	0
Trade Payables	190	337	429	584	595	644	760	1,071	1,302	870
Others Liabilities ⓘ	235	315	439	567	584	589	762	1,066	1,236	1,335
Total Liabilities ⓘ	1,050	1,391	1,758	2,386	2,352	2,543	3,093	3,907	4,540	4,316
Fixed Assets
Gross Block	296	160	295	378	620	796	1,081	1,352	1,652	1,931
Accumulated Depreciation	209	31	86	153	249	380	537	761	984	1,224
Net Fixed Assetsⓘ	87	129	209	226	371	416	544	592	668	708
CWIP ⓘ	149	210	232	360	220	161	131	212	204	283
Investmentsⓘ	96	92	62	24	213	117	84	136	33	160
Inventories	112	129	256	489	328	355	477	830	1,060	894
Trade Receivables	347	512	606	830	739	921	1,094	1,319	1,675	1,463
Cash Equivalents	67	53	85	66	81	104	212	147	84	33
Others Assetsⓘ	192	266	309	391	399	469	551	672	817	775
Total Assets ⓘ	1,050	1,391	1,758	2,386	2,352	2,543	3,093	3,907	4,540	4,316

Cash Flow

(All Figures are in Crores.)

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Cash Flow From Operating Activity ⓘ	14	142	123	-15	513	53	202	277	140	163
PBT ⓘ	150	256	270	290	217	209	285	392	411	175
Adjustment ⓘ	-6	-24	10	58	106	92	129	236	132	51
Changes in Working Capital ⓘ	-66	-23	-119	-284	270	-186	-158	-279	-345	-20
Tax Paid ⓘ	-63	-67	-38	-79	-80	-62	-53	-72	-58	-44
Cash Flow From Investing Activity ⓘ	-25	-65	-75	-139	-314	24	-238	-183	-2	-178
Capex	-80	-129	-140	-201	-143	-176	-233	-234	-240	-272
Net Investments	58	25	15	38	-216	102	-56	23	94	-131
Others ⓘ	-3	39	49	24	46	99	51	28	144	225
Cash Flow From Financing Activityⓘ	16	-89	-20	132	-215	-60	44	-90	-98	-35
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0	0	0	0	0	0	0	0	0	0
Interest Paid ⓘ	0	0	0	0	-10	-2	-2	-1	-1	-2
Dividend Paid ⓘ	-18	-50	-18	-36	-36	-54	-18	-54	-54	-27
Others ⓘ	35	-39	-2	169	-169	-4	64	-35	-43	-7
Net Cash Flow ⓘ	6	-12	28	-22	-16	18	9	4	40	-51

Finance Ratio

Standalone Basis Consolidated Basis

PARTICULARS	Mar'15	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24
Ratios
ROE (%)	17.72	26	23.2	19.78	12.87	15.45	14.91	17.49	17.39	6.65
ROCE (%)	27.44	38.57	34.12	28.66	19.55	17.99	20.76	24.29	22.78	9.52
Asset Turnover Ratio	0.84	0.77	0.72	0.71	0.68	0.66	0.72	0.84	0.78	0.59
PAT to CFO Conversion(x)	0.14	0.83	0.65	-0.08	3.56	0.28	0.96	0.98	0.43	1.19
Working Capital Days
Receivable Days	150	168	181	178	179	188	181	149	165	220
Inventory Days	41	47	62	92	93	77	75	81	104	137
Payable Days	133	168	200	193	198	203	187	166	185	203

Sharda Cropchem Ltd Stock News

Sharda Cropchem Ltd FAQs

What is the share price of Sharda Cropchem?

Company share prices are keep on changing according to the market conditions. The closing price of Sharda Cropchem on 20-Dec-2024 16:59 is ₹792.7.

What is the market cap of Sharda Cropchem?

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Dec-2024 16:59 the market cap of Sharda Cropchem stood at ₹7,151.8.

What is the P/E ratio of Sharda Cropchem?

The latest P/E ratio of Sharda Cropchem as of 20-Dec-2024 16:59 is 29.65.

What is the P/B ratio of Sharda Cropchem?

The latest P/B ratio of Sharda Cropchem as of 20-Dec-2024 16:59 is 3.40.

What is the 52-week high and low of Sharda Cropchem?

The 52-week high of Sharda Cropchem is ₹886.4 and the 52-week low is ₹318.0.

What is the TTM revenue of Sharda Cropchem?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Sharda Cropchem is ₹2,932 ( Cr.) .

About Sharda Cropchem Ltd

Sharda Cropchem was incorporated as Sharda Worldwide Exports on March 12, 2004, in Mumbai, as a private limited company under the Companies Act, 1956. Initially the company began its operations through two sole proprietary firms, each set up by Ramprakash V. Bubna and Sharda R. Bubna. After incorporation as Sharda Worldwide Exports in 2004, the generic agrochemical business and non-agrochemical business conducted by both firms were transferred to the company. The company was converted into a public limited company and changed its name to Sharda Cropchem on September 18, 2013.

Sharda Cropchem is a crop protection chemical company engaged in the marketing and distribution of a wide range of formulations and generic active ingredients globally. It is also involved in order based procurement and supply of Belts, general chemicals, dyes and dye intermediates. It procures these non-agrochemical products, primarily, from the manufacturers in China or India and supplies them in over 35 countries across Australia, Asia, Europe, North America and Latin America. The company has recently entered into the biocide segment and has acquired several registrations from the existing registration holders, primarily, in Europe.

As of August 5, 2014, the company had over 180 Good Laboratory Practices (GLP) certified dossiers and as of July 15, 2014, it owned over 1,040 registrations for formulations and over 155 registrations for generic active ingredients across Europe, NAFTA, Latin America and Rest of the World.

The companyâ€™s library of dossiers gives it a competitive edge and facilitates in seeking registrations in different countries in a time efficient manner. This also fosters its ability to operate in and distribute diversified range of formulations and generic active ingredients globally including highly regulated markets, which would not be permitted without such registrations. As of August 5, 2014, it has filed over 500 applications for seeking registrations globally which are pending at different stages.

Milestones: In November 2011, the company acquired 76% stake in Axis Crop Science, which is a company focused on marketing and distribution of formulations in India.